

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

August 23, 2017

**BSE Limited**

1<sup>st</sup> Floor, P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**

Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East),  
Mumbai – 400 051

Re.: **Press Release**

Dear Sir / Madam,

We enclose herewith a copy of press release dated August 23, 2017 titled "Zydus receives final approval from the USFDA for Ziprasidone Hydrochloride Capsules".


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**



**UPEN H. SHAH**  
**COMPANY SECRETARY**

Encl.: As above

## **Zydus receives final approval from the USFDA for Ziprasidone Hydrochloride Capsules**

*Ahmedabad, 23 August 2017*

Zydus Cadila has received the final approval from the USFDA to market Ziprasidone Hydrochloride Capsules in strengths of 20 mg, 40 mg, 60 mg, and 80 mg. Ziprasidone, an antipsychotic medication, is used to treat schizophrenia and the manic symptoms of bipolar disorder (manic depression). The drug will be manufactured at the group's formulations manufacturing facility at the Pharma SEZ, Ahmedabad.

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

\*\*\*